These data supported our hypothesis that cypripedin suppresses lung cancer mesenchyme-like phenotypes and that the underlying mechanism involves the inhibition of Akt that leads to the stimulation of GSK-3β-mediated Slug degradation. The gene discussed is SNAI2; the disease is lung cancer.